PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-60.51%
Both yoy net incomes decline, with CRK at -115.11%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
1.78%
D&A growth well above CRK's 2.77%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
-47.06%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
9.52%
Less SBC growth vs. CRK's 19.36%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
-408.26%
Both reduce yoy usage, with CRK at -149.08%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
104.76%
AR growth is negative or stable vs. CRK's 697.97%, indicating tighter credit discipline. David Dodd would confirm it doesn't hamper sales volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-774.16%
Negative yoy usage while CRK is 307.30%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
69.22%
Lower 'other non-cash' growth vs. CRK's 493.56%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
-49.79%
Both yoy CFO lines are negative, with CRK at -24.83%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
5.65%
Some CapEx rise while CRK is negative at -4.56%. John Neff would see competitor possibly building capacity while we hold back expansions.
-378.04%
Both yoy lines negative, with CRK at -75.00%. Martin Whitman sees an overall caution or integration phase for both companies’ expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
103.72%
Growth well above CRK's 107.44%. Michael Burry would suspect heavier intangible or side spending overshadowing competitor’s approach, risking short-term FCF.
-5.08%
We reduce yoy invests while CRK stands at 3.75%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
-1.20%
We cut debt repayment yoy while CRK is 55.56%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
No Data
No Data available this quarter, please select a different quarter.
-371.70%
We cut yoy buybacks while CRK is 0.00%. Joel Greenblatt would question if competitor is gaining a per-share edge unless expansions justify holding cash here.